The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Bahrt Kenneth since 2011.
The trader's CIK number is 1527197.
At the time of the last reporting, Bahrt Kenneth was the SVP, Chief Medical Officer of Outlook Therapeutics, Inc.. (stock ticker symbol OTLK).
Also see all insider trading activities at Outlook Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2018 | ONS | 0 | $0 | 7,700 | $6,506 | 0 | $0 |
| 2017 | ONS | 0 | $0 | 26,165 | $29,566 | 0 | $0 |
| 2016 | ONS | 2,000 | $0 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2013 | SVNT | 0 | $0 | 109,761 | $38,329 | 0 | $0 |
| 2012 | SVNT | 0 | $0 | 5,950 | $4,519 | 0 | $0 |
| 2011 | SVNT | 8,000 | $24,816 | 0 | $0 | 0 | $0 |
1. Outlook Therapeutics, Inc. (ONS)
2. Savient Pharmaceuticals Inc (SVNT)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-06-25 | ONS | Sale | 7,700 | .84 | 6,506 |
| 2017-12-22 | ONS | Sale | 26,165 | 1.13 | 29,566 |
| 2016-05-13 | ONS | Buy | 2,000 | .00 | 0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2013-10-15 | SVNT | Sale | 70,211 | .08 | 5,757 |
| 2013-10-16 | SVNT | Sale | 8,000 | .07 | 584 |
| 2013-04-30 | SVNT | Sale | 1,250 | .74 | 925 |
| 2013-02-04 | SVNT | Sale | 29,000 | 1.02 | 29,724 |
| 2013-01-31 | SVNT | Sale | 1,300 | 1.03 | 1,339 |
| 2012-10-31 | SVNT | Sale | 1,000 | 1.45 | 1,450 |
| 2012-08-01 | SVNT | Sale | 4,950 | .62 | 3,069 |
| 2011-11-16 | SVNT | Buy | 5,000 | 2.59 | 12,945 |
| 2011-09-14 | SVNT | Buy | 3,000 | 3.96 | 11,871 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Bahrt Kenneth (SVP, Chief Medical Officer of Outlook Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.